ChAdOx1 nCoV-19, the COVID-19 vaccine developed by Oxford, is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein. As the world is grappling with thousands of deaths and lakhs of coronavirus-infected cases, there is some hope as the world’s top university Oxford has announced its vaccine is entering Phase 1 clinical trials in humans.
In a press release, University of Oxford stated that its researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) on Friday for their upcoming ChAdOx1 nCoV-19 vaccine trial in England’s Thames Valley. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still.
“This is a significant development in humanity’s fight against the SARS-CoV-2 virus, which has already claimed more than 25000 lives across the world with over half a million confirmed cases”, Prof Vasan told The Hindu from Australia.
